The SMRT coregulator enhances growth of estrogen receptor-α-positive breast cancer cells by promotion of cell cycle progression and inhibition of apoptosis

Endocrinology (United States)

Volumn 155, Issue 9, 2014, Pages 3251-3261

  Blackmore, Julia K ^a   Karmakar, Sudipan ^a,b   Gu, Guowei ^a   Chaubal, Vaishali ^a   Wang, Liguo ^a   Li, Wei ^a,c   Smith, Carolyn L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; SHORT HAIRPIN RNA; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; SMALL INTERFERING RNA; TRIPHENYLTETRAZOLIUM; ESTROGEN RECEPTOR ALPHA, HUMAN; NCOR2 PROTEIN, HUMAN;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; COLONY FORMATION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MONOLAYER CULTURE; PROTEIN DEPLETION; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; FEMALE; GENETICS; METABOLISM; PATHOPHYSIOLOGY;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MCF-7 CELLS; NUCLEAR RECEPTOR CO-REPRESSOR 2;

EID: 84907062674     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1002     Document Type: Article

References (56)

1. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486: 400-404.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
4. Yue W, Yager JD, Wang JP, Jupe ER, Santen RJ. Estrogen receptor-dependent and independent mechanisms of breast cancer carcino-genesis. Steroids. 2013;78:161-170.
5. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1988;48:246-253.
6. Nilsson S, Mäkelä S, Treuter E, et al. Mechanismsofestrogenaction. Physiol Rev. 2001;81:1535-1565.
7. Pestell RG. New roles of cyclin D1. Am J Pathol. 2013;183:3-9.
8. Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol. 2013;8:135-155.
9. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aro-matase inhibitors, and breast cancer. J Steroid Biochem Mol Biol. 2011;125:13-22.
10. Jenuwein T, Allis CD. Translating the histone code. Science. 2001; 293:1074-1080.
11. Chen J, Kinyamu HK, Archer TK. Changes in attitude, changes in latitude: nuclear receptors remodeling chromatin to regulate transcription. Mol Endocrinol. 2006;20:1-13.
12. Lonard DM, O'malley BW. Nuclear receptor coregulators: judges, juries, and executionersofcellular regulation. Molecular Cell. 2007; 27:691-700.
13. Frietze S, Lupien M, Silver PA, Brown M. CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1. Cancer Res. 2008;68:301-306.
14. Peterson TJ, Karmakar S, Pace MC, Gao T, Smith CL. The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcrip-tional activity. Mol Cell Biol. 2007;27:5933-5948.
15. Karmakar S, Foster EA, Smith CL. Unique rolesofp160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity. Endocrinology. 2009;150:1588-1596.
16. Hudelist G, Czerwenka K, Kubista E, Marton E, Pischinger K, Singer CF. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res Treat. 2003;78:193-204.
17. List HJ, Reiter R, Singh B, Wellstein A, Riegel AT. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat. 2001;68:21-28.
18. Privalsky ML. The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu Rev Physiol. 2004;66:315-360.
19. Karmakar S, Gao T, Pace MC, Oesterreich S, Smith CL. Cooperative activation of cyclin D1 and progesterone receptor gene expression by the SRC-3 coactivator and SMRT corepressor. Mol Endocrinol. 2010;24:1187-1202.
20. Green AR, Burney C, Granger CJ, et al. The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. Breast Cancer Res Treat. 2008;110:427-437.
21. Smith CL, Migliaccio I, Chaubal V, et al. Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence. Breast Cancer Res Treat. 2012;136:253-265.
22. van Agthoven T, Sieuwerts AM, Veldscholte J, et al. CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer. Brit J Cancer. 2009;101:1824-1832.
23. Haiman CA, Garcia RR, Hsu C, et al. Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort. BMC Cancer. 2009;9:43.
24. Liao S, Desouki MM, Gaile DP, et al. Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast. Genes Chromosomes Cancer. 2012;51:1067-1078.
25. Jepsen K, Solum D, Zhou T, et al. SMRT-mediated repression ofan H3K27 demethylase in progression from neural stem cell to neuron. Nature. 2007;450:415-419.
26. Grewal C, Hickmott J, Rentas S, Karagiannis J. A conserved histone deacetylase with a role in the regulation of cytokinesis in Schizo-saccharomyces pombe. Cell Div. 2012;7:13.
27. Rentas S, Saberianfar R, Grewal C, et al. The SET domain protein, Set3p, promotes the reliable execution of cytokinesis in Schizosac-charomyces pombe. PLoS ONE. 2013;7:e31224.
28. Ishii S, Kurasawa Y, Wong J, Yu-Lee LY. Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-mi-crotubule attachment. Proc Natl Acad Sci USA. 2008;105:4179-4184.
29. Fadri-Moskwik M, Weiderhold KN, Deeraksa A, et al. Aurora B is regulated by acetylation/deacetylation during mitosis in prostate cancer cells. FASEB J. 2012;26:4057-4067.
30. Eot-Houllier G, Fulcrand G, Watanabe Y, Magnaghi-Jaulin L, Jau-lin C. Histone deacetylase 3 is required for centromeric H3K4 deacetylation and sister chromatid cohesion. Genes Dev. 2008;22: 2639-2644.
31. Li Y, Kao GD, Garcia BA, et al. Anovel histone deacetylase pathway regulates mitosisbymodulating auroraBkinase activity. Gene, Dev. 2006;20:2566-2579.
32. Guenther MG, Barak O, Lazar MA. The SMRT and N-CoR core-pressors are activating cofactors for histone deacetylase 3. Mol Cell Biol. 2001;21:6091-6101.
33. You SH, Lim HW, Sun Z, Broache M, Won KJ, Lazar MA. Nuclear receptor co-repressors are required for the histone-deacetylase activity of HDAC3 in vivo. Nat Struct Mol Biol. 2013;20:182-187.
34. Giordano C, Cui Y, Barone I, et al. Growth factor-induced resis-tancetotamoxifenisassociated withamutationofestrogen receptor alpha and its phosphorylation at serine 305. Breast Cancer Res Treat. 2010;119:71-85.
35. Karmakar S, Foster EA, Blackmore JK, Smith CL. Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line. Endocr Relat Cancer. 2011;18:113-127.
36. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. Ge-nePattern 2.0. Nat Genet. 2006;38:500-501.
37. Huangda W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44-57.
38. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1-13.
39. Keeton EK, Brown M. Cell cycle progression stimulated by tamox-ifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol. 2005;19:1543-1554.
40. Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol. 1998;18:4499-4508.
41. Yu X, Zhang X, Dhakal IB, Beggs M, Kadlubar S, Luo D. Induction of cell proliferation and survival genes by estradiol-repressed mi-croRNAs in breast cancer cells. BMC Cancer. 2012;12:29.
42. Zhu J, Lu X, Hua KQ, Sun H, Yu YH, Feng YJ. Oestrogen receptor a mediates 17/3-estradiol enhancement of ovarian cancer cell motility through up-regulation of survivin expression. Arch Gynecol Obstet. 2012;286:729-737.
43. Sanna MG, da Silva Correia J, Luo Y, et al. ILPIP, a novel anti-apoptotic protein that enhances XIAP-mediated activation of JNK1 and protection against apoptosis. J Biol Chem. 2002;277:30454-30462.
44. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673-682.
45. Liston P, Fong WG, Kelly NL, et al. Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol. 2001;3: 128-133.
46. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestro-gen, 4-hydroxytamoxifen. Mol Endocrinol. 1997;11:657-666.
47. Cheng X, Kao HY. G protein pathway suppressor 2 (GPS2) is a transcriptional corepressor important for estrogen receptor alpha-mediated transcriptional regulation. J Biol Chem. 2009;284: 36395-36404.
48. Planas-Silva MD, Shang Y, Donaher JL, Brown M, Weinberg RA. AIB1 enhances estrogen-dependent induction of cyclin D1 expression. Cancer Res. 2001;61:3858-3862.
49. Park EJ, Schroen DJ, Yang M, Li H, Li L, Chen JD. SMRTe, a silencing mediator for retinoid and thyroid hormone receptors-extended isoform that is more related to the nuclear receptor corepressor. Proc Natl Acad Sci USA. 1999;96:3519-3524.
50. O'Reilly MA, Gazdar AF, Clark JC, Pilot-Matias TJ, Wert SE, Hull WM, Whitsett JA. Glucocorticoids regulate surfactant protein synthesis in a pulmonary adenocarcinoma cell line. Am J Physiol. 1989; 257:L385-L392.
51. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194-202.
52. Kittler R, Pelletier L, Heninger AK, et al. Genome-scale RNAi profiling of cell division in human tissue culture cells. Nat Cell Biol. 2007;9:1401-1412.
53. New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: Can we interpret the code? Mol Oncol. 2012;6:637-656.
54. Scafoglio C, Smolka M, Zhou H, Perissi V, Rosenfeld MG. The co-repressor SMRT delays DNA damage-induced caspase activation by repressing pro-apoptotic genes and modulating the dynamics of checkpoint kinase 2 activation. PLoS ONE. 2013;8:e59986.
55. Alrfaei BM, Vemuganti R, Kuo JS. microRNA-100 targets SMRT/NCOR2, reduces proliferation, and improves survival in glioblastoma animal models. PLoS ONE. 2013;8:e80865.
56. Stanya KJ, Liu Y, Means AR, Kao HY. Cdk2 and Pin1 negatively regulate the transcriptional corepressor SMRT. J Cell Biol. 2008; 183:49-61.